Several studies have demonstrated improvement in treatment response by inclusion of a VEGF inhibitor in several cancer types, including breast cancer [45], NSCLC [46], metastatic colorectal cancer [47] and renal cell carcinoma [48]. Here, VEGFA is linked to breast cancer.